Lesion | Treatment | Study | Outcome | Odds Ratio (XRT/SRT over US-SRT) (95% Confidence Limits) | |||||
---|---|---|---|---|---|---|---|---|---|
Recurrence | Local Control | ||||||||
(n) | (%) | (n) | Yu 2021: US-SRT | Moloney 2022: US-SRT | |||||
BCC | US-SRT | Yu (2021) | 6 | 0.9 | 698 | OR | p-value | OR | p-value |
Moloney (2022) | 16 | 1.1 | 1471 | ||||||
XRT/SRT | Lovett | 20 | 9.0 | 202 | 11.5 (4.6, 29.1) | ā<ā.0001 | 9.1 (4.6, 17.9) | ā<ā.0001 | |
Locke | 21 | 6.4 | 305 | 8.0 (3.2, 20.0) | ā<ā.0001 | 6.3 (3.3, 12.3) | ā<ā.0001 | ||
Silverman | 52 | 6.0 | 810 | 7.5 (3.2, 17.5) | ā<ā.0001 | 5.9 (3.3, 10.4) | ā<ā.0001 | ||
Cognetta | 22 | 3.1 | 690 | 3.7 (1.5, 9.2) | 0.0047 | 2.9 (1.5, 5.6) | 0.0012 | ||
All | 115 | 5.4 | 2007 | 7.1 (3.1,16.3) | ā<ā.0001 | 5.6 (3.3, 9.6) | ā<ā.0001 | ||
SCC | US-SRT | Yu (2021) | 4 | 0.7 | 544 | OR | p-value | OR | p-value |
Moloney (2022) | 7 | 0.8 | 926 | ||||||
XRT/SRT | Lovett | 14 | 18.9 | 60 | 31.7 (10.1, 99.5) | ā<ā.0001 | 30.9 (12.0, 79.3) | ā<ā.0001 | |
Locke | 15 | 15.2 | 84 | 24.3 (7.9, 74.9) | ā<ā.0001 | 23.6 (9.4, 59.5) | ā<ā.0001 | ||
Cognetta | 4 | 3.0 | 129 | 4.2 (1.0, 17.1) | 0.0438 | 4.1 (1.2, 14.2) | 0.0259 | ||
All | 33 | 10.8 | 273 | 14.8 (5.1, 43.3) | ā<ā.0001 | 14.4 (6.1, 33.9 | ā<ā.0001 | ||
SCCIS | US-SRT | Yu (2021) | 2 | 0.5 | 415 | OR | p-value | OR | p-value |
Moloney (2022) | 1 | 0.2 | 649 | ||||||
XRT/SRT | Cognetta | 19 | 2.2 | 842 | 4.7 (1.1, 20.2) | 0.0385 | 14.6 (2.0, 109.7) | 0.0090 |